ADAnn Driessen

Ann Driessen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ann Driessen has a total of 112 co-authors. Here are the top co-authors by number of shared publications:

  • Sven Francque

    Department of Gastroenterology and Hepatology, Antwerp University Hospital, University of Antwerp, Antwerp, Belgium

    4 shared publications
  • Thomas Vanwolleghem

    Department of Gastroenterology and Hepatology, Antwerp University Hospital, Antwerp, Belgium

    4 shared publications
  • Luisa Vonghia

    Department of Gastroenterology and Hepatology, Antwerp University Hospital, Antwerp, Belgium

    3 shared publications
  • An Verrijken

    Department of Endocrinology, Diabetology and Metabolic Diseases, Antwerp University Hospital, 2650 Edegem, Belgium

    2 shared publications
  • Geert Roeyen

    Department of Hepatobiliary Transplantation and Endocrine Surgery, Antwerp University Hospital and University of Antwerp, Edegem, Belgium

    2 shared publications
  • Luisa Vonghia

    Viral Hepatitis Research Group, Laboratory of Experimental Medicine and Pediatrics, Antwerp University, Antwerp, Belgium; Department of Gastroenterology and Hepatology, Antwerp University Hospital, Antwerp, Belgium; European Reference Network RARE-LIVER, United Kingdom

    2 shared publications

Latest Publications

  • Open Access

    The Dual Roles of Esophageal Submucosal Glands: Protection and Pathogenesis in Benign and Malignant Disease: A Scoping Review

    by Chun-Ting Chen, Michiel F. G. de Maat, Ann Driessen, Michael Doukas, Bas P. L. Wijnhoven, Maikel P. Peppelenbosch, Kausilia K. Krishnadath, Vincent T. Janmaat

    Background: Esophageal submucosal glands (SMGs) contribute to mucosal defense through bicarbonate, mucin, and reparative-factor secretion. Chronic reflux may impair these functions and remodel the glandular compartment, potentially linking SMG injury to reflux esophagitis, Barrett’s esophagus (BE), and esophageal adenocarcinoma (EAC). Objective: To map the human, animal, and in vitro literature on the physiological and pathological roles of esophageal SMGs and to identify evidence gaps relevant to reflux injury, BE, EAC, and endoscopic therapy. Methods: This scoping review was reported in accordance with PRISMA-ScR. Embase, Web of Science, PubMed, and Google Scholar were searched from inception to 15 January 2025. Two reviewers independently screened records against prespecified eligibility criteria. The protocol was not registered. Results: The review included 97 full-text publications and 7 conference abstracts. The full-text set comprised 89 original studies and 8 reviews; review articles were used for context and citation tracing rather than counted as independent primary evidence. The mapped literature supports secretory and reparative functions of SMGs and documents injury-associated remodeling, including loss of mucinous acini and expansion of atrophic, oncocytic, or duct-like phenotypes. Marker expression, spatial continuity, and clonal observations are compatible with glandular participation in repair and Barrett-associated biology, but do not establish a unique cell of origin and lineage relationships remain unresolved. Conclusions: Esophageal SMGs occupy a plausible interface between mucosal protection and pathological plasticity. The most consequential gaps are the lack of longitudinal human evidence, source-resolved lineage information, standardized reporting of glandular phenotypes, and human models that reproduce reflux exposure and the stromal niche.

  • Open Access

    A liver gene signature links liver cancer risk in chronic viral hepatitis to intrahepatic IgA plasma cells

    by Nicolaas Van Renne, Fleur Ballet, Stijn Van Hees, Bart Cuypers, Arno Furquim D’ALmeida, Axelle Vanderlinden, Pieter Meysman, Jordan J. Feld, Paloma Sangro del Alcázar, Stefan Bourgeois, et al.


  • Open Access

    Muscle fat content is strongly associated with NASH: A longitudinal study in patients with morbid obesity

    by Maxime Nachit, Wilhelmus J. Kwanten, Jean-Paul Thissen, Bart Op De Beeck, Luc Van Gaal, Luisa Vonghia, An Verrijken, Ann Driessen, Yves Horsmans, Sven Francque, et al.


  • Open Access

    Non-Alcoholic Steatohepatitis Decreases Microsomal Liver Function in the Absence of Fibrosis

    by Wim Verlinden, Eugénie Van Mieghem, Laura Depauw, Thomas Vanwolleghem, Luisa Vonghia, Jonas Weyler, Ann Driessen, Dirk Callens, Laurence Roosens, Eveline Dirinck, et al.

    The incidence of non-alcoholic fatty liver disease (NAFLD) is rising across the globe, with the presence of steatohepatitis leading to a more aggressive clinical course. Currently, the diagnosis of non-alcoholic steatohepatitis (NASH) is based on histology, though with the high prevalence of NAFLD, a non-invasive method is needed. The 13C-aminopyrine breath test (ABT) evaluates the microsomal liver function and could be a potential candidate. We aimed to evaluate a potential change in liver function in NASH patients and to evaluate the diagnostic power of ABT to detect NASH. We performed a retrospective analysis on patients suspected of NAFLD who underwent a liver biopsy and ABT. 440 patients were included. ABT did not decrease in patients with isolated liver steatosis but decreased significantly in the presence of NASH without fibrosis and decreased even further with the presence of significant fibrosis. The predictive power of ABT as a single test for NASH was low but improved in combination with ALT and ultrasonographic steatosis. We conclude that microsomal liver function of patients with NASH is significantly decreased, even in the absence of fibrosis. The ABT is thus a valuable tool in assessing the presence of NASH; and could be used as a supplementary diagnostic tool in clinical practice.


  • Open Access

    PDX1 DNA Methylation Distinguishes Two Subtypes of Pancreatic Neuroendocrine Neoplasms with a Different Prognosis

    by Gitta Boons, Timon Vandamme, Joe Ibrahim, Geert Roeyen, Ann Driessen, Dieter Peeters, Ben Lawrence, Cristin Print, Marc Peeters, Guy Van Camp, et al.

    DNA methylation is a crucial epigenetic mechanism for gene expression regulation and cell differentiation. Furthermore, it was found to play a major role in multiple pathological processes, including cancer. In pancreatic neuroendocrine neoplasms (PNENs), epigenetic deregulation is also considered to be of significance, as the most frequently mutated genes have an important function in epigenetic regulation. However, the exact changes in DNA methylation between PNENs and the endocrine cells of the pancreas, their likely cell-of-origin, remain largely unknown. Recently, two subtypes of PNENs have been described which were linked to cell-of-origin and have a different prognosis. A difference in the expression of the transcription factor PDX1 was one of the key molecular differences. In this study, we performed an exploratory genome-wide DNA methylation analysis using Infinium Methylation EPIC arrays (Illumina) on 26 PNENs and pancreatic islets of five healthy donors. In addition, the methylation profile of the PDX1 region was used to perform subtyping in a global cohort of 83 PNEN, 2 healthy alpha cell and 3 healthy beta cell samples. In our exploratory analysis, we identified 26,759 differentially methylated CpGs and 79 differentially methylated regions. The gene set enrichment analysis highlighted several interesting pathways targeted by altered DNA methylation, including MAPK, platelet-related and immune system-related pathways. Using the PDX1 methylation in 83 PNEN, 2 healthy alpha cell and 3 healthy beta cell samples, two subtypes were identified, subtypes A and B, which were similar to alpha and beta cells, respectively. These subtypes had different clinicopathological characteristics, a different pattern of chromosomal alterations and a different prognosis, with subtype A having a significantly worse prognosis compared with subtype B (HR 0.22 [95% CI: 0.051–0.95], p = 0.043). Hence, this study demonstrates that several cancer-related pathways are differently methylated between PNENs and normal islet cells. In addition, we validated the use of the PDX1 methylation status for the subtyping of PNENs and its prognostic importance.


  • Risk of Development of More-advanced Lesions in Patients With Inflammatory Bowel Diseases and Dysplasia

    by Anneline Cremer, Pieter Demetter, Martine De Vos, Jean-François Rahier, Filip Baert, Tom Moreels, Elisabeth Macken, Edouard Louis, Liesbeth Ferdinande, Caroline Fervaille, et al.


  • Nivolumab and anti-HCV activity, a case report

    by Laura Wuyts, Annelies Janssens, Luisa Vonghia, Peter Michielsen, Jo Raskin, Ann Driessen, Stijn Van Hees, Sven Francque, Thomas Vanwolleghem

    Exhaustion of antigen-specific T-cells in order to escape immune destruction is frequently seen in chronic viral infection and different types of cancer. Blockade of overexpressed negative co-stimulatory pathways, a process known as immune checkpoint modulation, is a promising novel therapy that could improve the treatment of liver diseases with features of T cell exhaustion. We present a case of a 54-year-old hepatitis C virus (HCV) positive patient with an acute flare of hepatitis during nivolumab treatment for a stage IV lung carcinoma, an anti-programmed death-1 (PD-1) immunotherapy. Retrospective testing of HCV RNA documented infection more than 6 months ago. Nivolumab treatment was associated with an alanine aminotransferase (ALT) flare reaching a peak value of 663 U/L, along with bilirubin levels of 0.74 mg/dL and no signs of coagulopathy. The assumption of a nivolumab-associated autoimmune hepatitis led to the interruption of the immune checkpoint inhibitor treatment. However, a subsequent 1-log decrease of HCV RNA load was noticed, which raised the possibility of an immune reconstitution against the HCV-infected hepatocytes with cell lysis. Liver biopsy specimen demonstrated no evidence for autoimmune liver disease or fibrosis. Clinical evolution was favorable and serum transaminases returned to normal levels and HCV RNA load increased to baseline values following nivolumab cessation. The current case suggests an anti-HCV activity of anti-PD-1 treatment in the setting of concomitant HCV viremia and lung carcinoma.


  • Dysplasia in Inflammatory Bowel Disease

    by Ann Driessen, Karen Paula Geboes, Olivier Dewit, Anne Jouret-Mourin


  • Estimation of the future remnant liver function is a better tool to predict post-hepatectomy liver failure than platelet-based liver scores

    by T. Chapelle, B. Op de Beeck, A. Driessen, G. Roeyen, B. Bracke, V. Hartman, I. Huyghe, S. Morrison, D. Ysebaert, S. Francque